Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn

Already behind in the PARP inhibitor race, Clovis Oncology’s Rubraca has at least won a reserved backing from England’s drug cost watchdog that helps level the playground in the U.K. region. Now, the late-comer will have to face two Big Pharma companies in their home country.